MRVI — Maravai LifeSciences Holdings, Inc.

Summary of Maravai LifeSciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $49.9 million, an 18% increase year-over-year when excluding $14.3 million from high-volume COVID CleanCap sales in Q4 2024.
• Full Year Revenue: $185.7 million, exceeding guidance by $700,000.
• GAAP Net Loss: $63 million for Q4, compared to a loss of $46.1 million in Q4 2024. Full year loss was $230.8 million, an improvement from $259.6 million in 2024.
• Adjusted EBITDA: Positive $536,000 for Q4, marking the first positive adjusted EBITDA in four quarters, compared to negative $1.1 million in Q4 2024. Full year adjusted EBITDA was negative $31.2 million.
• EPS: Basic and diluted loss per share was $0.24 for Q4, compared to a loss of $0.18 in Q4 2024.

2. Strategic Updates and Business Highlights

• Segment Renaming: Reportable segments renamed to TriLink (nucleic acid production) and Cygnus (biologic safety testing) for better alignment with branding.
• Operational Improvements: Successful restructuring led to over $65 million in cost savings, exceeding initial targets. Positive adjusted EBITDA indicates improved operational execution.
• Product Launches: Strong demand for new products, including GMP enzymes and ModTail technology, which generated over $0.5 million in 2025 and has seen increased adoption in 2026.
• Customer Engagement: Enhanced direct engagement with customers has strengthened TriLink's market position, with all top five customers increasing their purchases.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $200 million to $210 million, representing growth of 8% to 13% over 2025.
• Adjusted EBITDA Guidance: Projected at $18 million to $20 million for 2026, reflecting significant improvement from 2025.
• TriLink Growth: Anticipated low double-digit growth driven by GMP consumables, while Cygnus is expected to grow low to mid-single digits.

4. Bad News, Challenges, or Points of Concern

• GAAP Losses: Continued GAAP net losses indicate ongoing financial challenges, though improvements are noted.
• Market Dynamics: The company faces a competitive landscape, particularly in the mRNA sector, with ongoing scrutiny and regulatory challenges.
• Dependence on Large Orders: Revenue is subject to lumpiness due to the nature of large orders, which can create uncertainty in forecasting.

5. Notable Q&A Insights

• Order Volume: Management noted that current order volumes are significantly higher than the previous year, particularly in GMP consumables and larger discovery orders.
• GMP Consumables: Growth is attributed to a diverse customer base rather than reliance on a few key programs, indicating a healthy demand environment.
• Cost Structure: The company is expected to maintain a leaner cost structure moving forward, with continued focus on operational efficiencies.
• Regulatory Environment: Management expressed cautious optimism regarding FDA guidance, particularly in cell and gene therapy, while noting low exposure to vaccine-related revenue.

Overall, Maravai LifeSciences is positioned for growth in 2026, driven by strategic operational improvements and product innovations, despite facing challenges related to market dynamics and ongoing financial losses.